Forte Biosciences Inc (FBRX)
Healthcare
Biotechnology
76.60 $
-0.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Forte Biosciences Inc (FBRX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 91.9% of the shares are freely tradable; institutional investors hold 74.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
74.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
91.9%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
21Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Federated Hermes Inc | 8.62 | 1,765,516 | +0.0 | 03/31/2026 |
| Fred Alger Management, LLC | 6.22 | 1,273,965 | -12.8 | 03/31/2026 |
| Orbimed Advisors, LLC | 5.84 | 1,196,955 | +0.0 | 03/31/2026 |
| HHG PLC | 5.80 | 1,188,060 | -16.7 | 03/31/2026 |
| Affinity Asset Advisors, LLC | 4.94 | 1,011,890 | +2.3 | 03/31/2026 |
| MPM Oncology Impact Management LP | 4.89 | 1,000,682 | +0.0 | 03/31/2026 |
| Adage Capital Partners Gp LLC | 4.64 | 950,000 | +185.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Federated Hermes Kaufmann R | 5.08 | 1,040,900 | +0.0 | 03/31/2026 |
| Federated Hermes Kaufmann Growth | 5.08 | 1,040,900 | +0.0 | 03/31/2026 |
| Federated Hermes Kaufmann Small Cap Grow | 3.43 | 702,400 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.